Business
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two upcoming presentations, – one at the American College of Clinical Pharmacology Annual Meeting being held September 25-27 in Bethesda, Maryland, and another at the 12th Annual World Clinical Biomarkers & CDx Summit being held September 26-29 in Boston, Massachusetts.\n\nThe presentations will provide insight into SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming primary resistance to checkpoint therapy in advanced cancer patients. Combination therapy with selective TGFβ1 blockade may modulate the tumor microenvironment, allowing for immune cell infiltration and potential improvements in the response rate and survival time of cancer patients.\n\nSpecifically, the ACCP presentation will include new pharmacokinetic data from the Phase 1 dose escalation study (DRAGON Part A). The presentation at the World Clinical Biomarkers & CDx Summit includes a discussion of pre-clinical validation studies to assess biomarker utility, overcoming challenges and hurdles that create barriers to assay translatability to the clinic, and early clinical biomarker data including image-based analysis.\n\nDetails of the presentations are as follows:\n\nACCP Annual Meeting:\n\nTitle: Preliminary Population Pharmacokinetic Modeling of SRK-181 from Phase 1 Dose Escalation Study\nPresentation Type: Poster 015\nPresenter: Amanda Hoerres, PharmD, independent consultant for Scholar Rock and Senior Scientist II, Clinical Pharmacologist, Vanadro Consulting\nDate/Time: September 25, 5-7 p.m. ET\n\n12th Annual World Clinical Biomarkers & CDx Summit:\n\nTitle: Development of a Comprehensive Biomarker Strategy for the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON\nPresentation Type: Oral\nPresenter: Si Tuen Lee-Hoeflich, Senior Director, Translational Sciences at Scholar Rock\nDate/Time: September 28, 3:25 p.m. ET\n\nThe presentations will be made available in the Publications & Posters section of Scholar Rock’s website following the conferences.\n\nFor conference information, visit https://accp1.org/ and https://world-cdx.com/\n\nAbout SRK-181\n\nSRK-181 is a select...